Forty three Eighteen Advisors LLC Buys Shares of 21,894 Merck & Co., Inc. $MRK

Forty three Eighteen Advisors LLC purchased a new position in Merck & Co., Inc. (NYSE:MRK) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 21,894 shares of the company’s stock, valued at approximately $2,634,000. Merck & Co., Inc. accounts for about 2.0% of Forty three Eighteen Advisors LLC’s portfolio, making the stock its 14th largest position.

Other institutional investors and hedge funds have also modified their holdings of the company. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $25,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. in the 4th quarter worth $26,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. during the fourth quarter valued at $26,000. IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. during the fourth quarter valued at $31,000. Finally, High Note Wealth LLC grew its holdings in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on MRK. Citigroup began coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target for the company. Wells Fargo & Company lifted their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 8th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. UBS Group raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $120.00 price target on shares of Merck & Co., Inc. in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.94.

Merck & Co., Inc. Trading Down 0.1%

Shares of MRK stock opened at $127.47 on Friday. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $131.74. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market capitalization of $314.83 billion, a PE ratio of 35.91, a PEG ratio of 4.40 and a beta of 0.19. The stock has a fifty day simple moving average of $120.11 and a two-hundred day simple moving average of $116.94.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the business earned $2.22 earnings per share. The business’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts predict that Merck & Co., Inc. will post 3.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were issued a $0.85 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approval of LIPFENDRA gives Merck its first oral PCSK9 inhibitor, opening a new revenue stream in cardiovascular care and strengthening its non-oncology portfolio. Reuters article on FDA approval
• Positive Sentiment: Analysts highlighted continued oncology pipeline progress, including FDA acceptance of multiple regulatory filings and Merck’s broader effort to offset the eventual 2028 Keytruda patent cliff. Seeking Alpha article on pipeline expansion
• Neutral Sentiment: Coverage also noted that Lipfendra’s launch is expected soon and that the drug could become a major product over time, though sales will depend on uptake, pricing, and competition from existing cholesterol therapies. Zacks article on Lipfendra launch
• Neutral Sentiment: There was also a rumor that Merck may be in a takeover battle for genomics company Personalis, but this appears speculative and is not confirmed. Yahoo Finance article on Personalis rumor

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.